Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SHR 3680

Next Previous
Drug Profile

SHR 3680

Alternative Names: SHR3680

Latest Information Update: 28 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jiangsu Hengrui Medicine Co.
  • Class Antineoplastics
  • Mechanism of Action Androgen receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Prostate cancer

Most Recent Events

  • 28 Oct 2019 No recent reports of development identified for phase-I development in Prostate-cancer(Metastatic disease, Monotherapy, Second-line therapy or greater) in Australia (PO, Tablet)
  • 08 Apr 2019 Phase-II clinical trials in Prostate cancer (Combination therapy, Metastatic disease, Second-line therapy or greater, Hormone refractory) in China (PO) (NCT04102124)
  • 08 Apr 2019 Phase-II clinical trials in Prostate cancer (Hormone refractory, Metastatic disease, Monotherapy, Second-line therapy or greater) in China (PO) (NCT04102124)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top